Canaccord Genuity Reiterates a Buy on Boston Scientific Corporation (BSX)

​Boston Scientific Corporation (NYSE:BSX) is one of the Best Stocks to Buy for High Returns Heading into 2026. On October 23, William Plovanic from Canaccord Genuity reiterated a Buy rating on Boston Scientific Corporation (NYSE:BSX) with a price target of $132.

​The rating comes after the company, on October 22, released results for its fiscal third quarter 2025. The company topped EPS and revenue estimates by $0.04 and $90.87 million, respectively. The analyst noted that the EPS of $0.75 was also significantly higher than the firm’s estimation of $0.70. This was primarily driven by a substantial improvement in gross margins.

​Moreover, Boston Scientific Corporation (NYSE:BSX) also raised its full-year guidance and now projects 20% growth and an adjusted EPS in the range of $3.02 to $3.04. The firm believes some of the key drivers of the company’s growth are its Watchman and Farapulse products, continued investment in growth, and expected label expansions of existing products.

​Boston Scientific Corporation (NYSE:BSX) develops and markets medical devices for various interventional specialties. The company’s products address gastrointestinal, urological, neurological, and cardiovascular conditions using minimally invasive technologies.

While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.